Mazdutide (IBI362, LY3305677, CAS 2259884-03-0) is a synthetic oxyntomodulin analogue and a long-acting dual agonist of the GLP-1 receptor and glucagon receptor (GLP-1R/GCGR co-agonist). It is derived from the 37-amino-acid peptide oxyntomodulin and engineered with fatty-acid acylation for once-weekly albumin binding and DPP-IV resistance. Its mechanism couples two complementary pathways: GLP-1R agonism drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety, while GCGR agonism increases energy expenditure, thermogenesis, hepatic fat oxidation, and lipolysis. The glucagon-driven hyperglycemic signal is offset by GLP-1’s concurrent insulinotropic and glucagonostatic actions, producing a net reduction in body weight with preserved glycemic control — the defining feature that distinguishes it from GLP-1-only agonists.

Semaglutide is a GLP-1 receptor-selective agonist; mazdutide is a dual GLP-1R/GCGR co-agonist. Semaglutide’s weight loss is driven almost entirely by appetite suppression and slowed gastric emptying — it reduces energy intake but does not materially increase energy expenditure. Mazdutide adds glucagon receptor agonism, which directly raises energy expenditure, thermogenesis, hepatic fat oxidation, and lipolysis. By pairing GLP-1R satiety with GCGR energy dissipation, mazdutide targets both sides of the energy-balance equation — reducing intake while increasing output. This is the mechanistic rationale for expecting greater and more durable weight loss than GLP-1 monotherapy, with GLP-1’s insulinotropic and glucagonostatic actions preventing glucagon-mediated hyperglycemia. Both compounds are supplied by UPOR Biotech strictly for research use.

Mazdutide is used in preclinical and discovery research across four primary areas: (1) obesity and weight-management research — modeling dual incretin-mediated weight loss and body-composition change; (2) type 2 diabetes and glycemic control research — studying glucose-dependent insulin secretion and glucagon suppression; (3) NASH/MASH and metabolic liver disease research — investigating hepatic fat oxidation, steatosis reduction, and liver fibrosis endpoints; and (4) energy expenditure and thermogenesis studies — quantifying GCGR-driven metabolic rate, brown/beige adipose activation, and lipolysis. It also serves as a reference compound for GLP-1R/GCGR pharmacology and next-generation incretin co-agonist screening.

Store lyophilized mazdutide at -20°C, protected from light and moisture, where it is stable for 2 years. Before reconstitution, briefly warm the vial to room temperature and centrifuge to collect the powder. Reconstitute in sterile water, PBS (pH 7.4), or dilute acetic acid to a convenient working concentration (commonly 1 mg/mL). Avoid vigorous vortexing — gently agitate or pipette to dissolve. Reconstituted solutions should be aliquoted and stored at -20°C, and repeated freeze-thaw cycles should be avoided to prevent peptide degradation and aggregation. For short-term use, reconstituted peptide may be held at 4°C for up to 1–2 weeks.

Every shipment includes a complete analytical package: Certificate of Analysis (COA) with HPLC purity (≥98.0%), peptide content, endotoxin (≤1.0 EU/mg), water content, and counter-ion confirmation; MSDS; HPLC chromatogram; mass spectrometry (MS) report confirming molecular weight (4563.06 g/mol); and endotoxin report. Manufacturing is supported by ISO 9001, cGMP-compliant processes, and FDA facility registration, with full lot traceability. All documentation is provided in English, and the product is supplied strictly as a Research Use Only (RUO) reagent — not for human diagnostic or therapeutic use.